ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 781.2 USD | +5.96% |
|
+5.84% | +35.40% |
| 03:38pm | Sector Update: Health Care Stocks Mixed Premarket Tuesday | MT |
| 03:28pm | Sector Update: Health Care | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
06:25am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
737.2
USD
Average target price
813.3
USD
Spread / Average Target
+10.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.40% | 664B | |
| +29.35% | 567B | |
| -7.22% | 354B | |
| +19.43% | 330B | |
| +4.56% | 286B | |
| +13.43% | 234B | |
| +5.22% | 199B | |
| -9.98% | 196B | |
| -4.71% | 148B | |
| -10.47% | 145B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept
